Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis

Archives of Internal Medicine

Volumn 164, Issue 18, 2004, Pages 2024-2030

  Lindsay, Robert ^a,b,i,j   Scheele, Wim H ^b,h   Neer, Robert ^b,c,j   Pohl, Gerhardt ^b   Adami, Silvano ^d   Mautalen, Carlos ^e   Reginster, Jean Yves ^b,f,i,k,l,m   Stepan, Jan J ^g   Myers, Stephen L ^b   Mitlak, Bruce H ^b  

^a HELEN HAYES HOSPITAL   (United States)

^b ELI LILLY AND COMPANY   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d UNIVERSITY OF VERONA   (Italy)

^e UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^f UNIVERSITY OF LIÈGE   (Belgium)

^g CHARLES UNIVERSITY   (Czech Republic)

^h PFIZER INC   (United States)

ⁱ Procter and Gamble ^*

^j MERCK RESEARCH LABORATORIES   (United States)

^k AMGEN INC   (United States)

^l GLAXOSMITHKLINE   (United Kingdom)

^m NPS Pharmaceuticals

more..

Author keywords

[No Author keywords available]

Indexed keywords

PARATHYROID HORMONE[1-34];

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MEDICAL PRACTICE; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; SCORING SYSTEM; SPINE RADIOGRAPHY; THORACIC SPINE; VERTEBRA FRACTURE;

AGED; BONE DENSITY; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; PARATHYROID HORMONE; RANDOMIZED CONTROLLED TRIALS; RISK REDUCTION BEHAVIOR; SPINAL FRACTURES; TERIPARATIDE; TIME FACTORS; TREATMENT OUTCOME; WITHHOLDING TREATMENT;

EID: 6344278780     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.164.18.2024     Document Type: Article

References (11)

1. Rubin MR, Cosman F, Lindsay R, Bilezikian JP. The anabolic effects of parathyroid hormone. Osteopoms Int. 2002;13:267-277.
2. Dempster DW, Cosman F, Kurland ES, et al. Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study. J Bone Miner Res. 2001;16:1846-1853.
3. Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001;344:1434-1441.
4. Vahle JL, Sato M, Long GG, et al. Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety. Toxicol Pathol. 2002;30:312-321.
5. Tashjian AH, Chabner BA. Clinical safety of recombinant human parathyroid hormone (1-34) in the treatment of osteoporosis in postmenopausal women and men [commentary]. J Bone Miner Res. 2002;17:1151-1161.
6. Jonsson B, Kanis J, Dawson A, Oden A, Johnell O. Effect and offset of effect of treatments for hip fracture on health outcomes. Osteoporos Int. 1999;10:193-199.
7. Bilezikian JP, Kurland ES. Therapy of male osteoporosis with parathyroid hormone. Calcif Tissue Int. 2001;69:248-251.
8. Genant HK, Wu CY, van Kuijk C, Nevitt MC. Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res. 1993;8:1137-1148.
9. Lu Y, Ye K, Mathur A, Hui S, Fuerst T, Genant H. Comparative calibration without a gold standard. Stat Med. 1997;16:1889-1905.
10. Lindsay R, Silverman SL, Cooper C, et al. Risk of new vertebral fracture in the year following a fracture. JAMA. 2001;285:320-323.
11. Cummings SR, Black DM, Pearson J, et al, for the Fracture Intervention Trial Research Group. Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. Am J Med. 2002;112:281-289.